Finding a sweet spot for leptin.

Med

National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Published: July 2021

Non-alcoholic fatty liver disease (NAFLD) is a growing public health problem that progresses to serious liver disease in some patients and for which there are no FDA-approved therapies. In this issue of Med, Akinci et al. present encouraging preliminary data showing that treatment with recombinant leptin has beneficial effects on NAFLD.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medj.2021.06.008DOI Listing

Publication Analysis

Top Keywords

liver disease
8
finding sweet
4
sweet spot
4
spot leptin
4
leptin non-alcoholic
4
non-alcoholic fatty
4
fatty liver
4
disease nafld
4
nafld growing
4
growing public
4

Similar Publications

Severe Maternal Morbidity Associated With Chronic Hypertension, Preeclampsia, and Gestational Hypertension.

JAMA Netw Open

January 2025

Magee-Womens Research Institute, Department of Obstetrics, Gynecology and Reproductive Sciences, Epidemiology and Clinical and Translational Research, University of Pittsburgh, Pittsburgh, Pennsylvania.

Importance: Chronic hypertension and preeclampsia are leading risk enhancers for maternal-neonatal morbidity and mortality. Severe maternal morbidity (SMM) indicators include heart, kidney, and liver disease, but studies have not excluded patients with preexisting diseases that define SMM. Thus, SMM risks for uncomplicated chronic hypertension specific to preeclampsia remain unclear.

View Article and Find Full Text PDF

Background: Hepatocellular carcinoma (HCC), the most common form of liver cancer, has a significant mortality rate, largely due to late diagnosis. Recent advances in medical research have demonstrated the potential of biomarkers for early detection. Moreover, the discovery and use of prognostic biomarkers offer a ray of hope in the fight against liver cancer.

View Article and Find Full Text PDF

Background: Helicobacter pylori bacteria colonize the gastric mucosa and contribute to the occurrence and development of gastrointestinal diseases. According to the WHO, H. pylori bacteria are considered class I carcinogen.

View Article and Find Full Text PDF

An insight on the additive impact of type 2 diabetes mellitus and nonalcoholic fatty liver disease on cardiovascular consequences.

Mol Biol Rep

January 2025

Department of Pharmaceutical Sciences & Technology, BIT Mesra, Ranchi, 835215, India.

Background: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are associated with a multifactorial complicated aetiology that is often coexisting and has a strong and distinct connection with cardiovascular diseases (CVDs). In order to accomplish effective and appropriate therapeutic strategies, a deeper understanding of the bidirectional interaction between NAFLD patients, NAFLD patients with T2DM, and NAFLD patients with CVDs is required to control the concomitant rise in prevalence of these conditions worldwide. This article also aims to shed light on the epidemiology and mechanisms behind the relationship between T2DM, NAFLD and the related cardiovascular consequences.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!